Product Overview
Strip the albumin anchor off CJC-1295 and what remains is modified growth hormone releasing factor 1-29, the peptide the catalogues label Mod GRF 1-29 or CJC-1295 no DAC. Generic Peptides stocks it as three freeze-dried vials: 2 mg, 5 mg and 10 mg. The sequence is a GHRH analogue with four substitutions that protect it from fast enzymatic breakdown, and the absence of the drug affinity complex is the single fact that defines its behaviour.
That difference is worth spelling out, because the two products share a name and almost nothing else. With the anchor the peptide rides on albumin and keeps growth hormone and IGF-1 high for days. Without it, clearance runs about thirty minutes and the pituitary releases hormone in one short burst. There is no multi-day IGF-1 elevation, no weekly rhythm and no plateau to speak of.
No human trial data exists for this variant, so the expectations below are drawn from the pharmacology of GHRH analogues rather than from measurements taken in people. It has no approved medicinal form in the United States or the European Union, and growth hormone releasing factors sit in WADA class S2, prohibited at all times. Where the sustained version suits a background level, this one suits a nightly pulse, and users comparing the two should read the long-acting CJC-1295 DAC entry alongside this one.
Dosage Protocol
Nothing below is an approved schedule. The concentration table is arithmetic for the vials on this page, and the amounts reflect vendor conventions in research descriptions.
| Item | Figure | Comment |
| Half-life | About 30 minutes | Subcutaneous; produces one pulse instead of a plateau |
| Vendor convention | 100-200 mcg per shot | One to three times a day; no single protocol is standard |
| Timing convention | Before sleep | Daily use, sometimes with a second injection |
| 2 mg vial plus 1 ml | 2 mg/ml | Ten units on a U-100 barrel carries 200 micrograms |
| 5 mg vial plus 2 ml | 2.5 mg/ml | Ten units carries 250 micrograms |
| 10 mg vial plus 2 ml | 5 mg/ml | Ten units carries 500 micrograms |
| Female | - | No verified female schedule appears in the sources |
A thirty minute clearance means the injection rhythm, not the individual amount, is what shapes the result. Someone who injects once and expects a day-long effect is using the wrong product rather than the wrong dose; the long-acting presentation exists for exactly that reason.
Suggested Protocols
The logic of pairing here is receptor-based. A GHRH analogue and a ghrelin-receptor secretagogue push the same output through two different doors, and that is the arrangement most research descriptions use. No controlled trial has tested the combinations.
Shelf neighbours with a different mechanism include Sermorelin, a shorter GHRH fragment with the longest clinical history of the group, and GHRP-6 where the appetite signal is the variable under study. Downstream of both sits IGF-1 LR3, which acts at the receptor level rather than on release.
What to Expect
- No human data on this variant. Every expectation is an extrapolation from GHRH analogue pharmacology, which is worth saying before anything else.
- A pulse, not a plateau. Roughly thirty minutes in circulation means growth hormone comes out in one short burst and then falls away.
- No multi-day IGF-1 rise. That behaviour belongs to the anchored version; here the marker does not stay elevated between shots.
- Daily injections. The rhythm is nightly, sometimes with a second dose, which is a commitment the weekly product does not ask for.
- Stronger release when paired. A ghrelin-receptor secretagogue gives a more pronounced growth hormone response, which is why the pairing is common in descriptions.
- Unconfirmed class effects. Fluid retention and glucose shifts are known for the class but are not confirmed for this variant.
- No approved form anywhere. There is no licensed product in the United States or the European Union.
Side Effects and Management
Most of what is reported here is ordinary for subcutaneous peptides. Where the sources refuse to commit to a figure for this variant, the entry says so rather than borrowing a number.
Post-Cycle Therapy and Research Monitoring
There is no post-cycle protocol for this peptide line. Nothing in the sources describes suppression of the body's own hormonal axis of the kind androgens cause, so the recovery question simply does not arise.
Storage is the same as for every other peptide in the line: powder cold, dark and dry; the mixed solution at 2-8 C for 28-30 days at most; no freezing. Because a 10 mg vial at 5 mg per ml stretches a long way at 100-200 microgram amounts, the realistic risk is a solution that outlives its own shelf life rather than a shortage.
